Due to its ability to reduce the risk of relapse, allogeneic stem cell transplantation (allo-SCT) is the optimal treatment strategy for adult patients with acute myeloid leukemia (AML). The European LeukemiaNet (ELN) group recommends the consideration of allo-SCT in fit adult patients with AML in CR1, who have a predicted relapse risk of 35-40% and a suitable donor. Risk stratification is based on clinical factors, such as age and gender, as well as cytogenetic risk based on karyotyping results. More recently, risk stratification using mutations of prognostic significance in genes such as FLT3, NPM1, ASXL1, RUNX1 and TP53, has also been included, as described in the 2017 ELN classification. However, disease relapse represents the major cause of treatment failure, and thus, optimizing the use of conditioning regimens and the administration of immunotherapy after allo-SCT is important in preventing relapse.
The objective of this collection is to deepen the general understanding of SCT in AML, to examine the cytogenetic and molecular risk factors predisposing patients to relapse by incorporating new study methods developed in recent years (i.e. next-generation sequencing), and to review alternative transplant strategies to allo-SCT, such as transplantation from haploidentical donors or cord blood stem cells. Additionally, this collection will address relapse prevention strategies leveraging immunotherapy and novel drugs. Finally, this collection will investigate the mechanisms of escape that leukemic cells can implement to avoid the control of the donor's immune system.
The collection will accept manuscripts in the following research areas:
- Haploidentical SCT in patients with AML
- Transplantation from alternative sources in patients with AML
- Molecular risk and relapse in AML
- Prevention of relapse with new drugs in patients with AML
- Leukemic mechanisms of escape during SCT
- Immunotherapy approaches after SCT in patients with AML
Important Note: Manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in any of the sections of Frontiers in Oncology.
Due to its ability to reduce the risk of relapse, allogeneic stem cell transplantation (allo-SCT) is the optimal treatment strategy for adult patients with acute myeloid leukemia (AML). The European LeukemiaNet (ELN) group recommends the consideration of allo-SCT in fit adult patients with AML in CR1, who have a predicted relapse risk of 35-40% and a suitable donor. Risk stratification is based on clinical factors, such as age and gender, as well as cytogenetic risk based on karyotyping results. More recently, risk stratification using mutations of prognostic significance in genes such as FLT3, NPM1, ASXL1, RUNX1 and TP53, has also been included, as described in the 2017 ELN classification. However, disease relapse represents the major cause of treatment failure, and thus, optimizing the use of conditioning regimens and the administration of immunotherapy after allo-SCT is important in preventing relapse.
The objective of this collection is to deepen the general understanding of SCT in AML, to examine the cytogenetic and molecular risk factors predisposing patients to relapse by incorporating new study methods developed in recent years (i.e. next-generation sequencing), and to review alternative transplant strategies to allo-SCT, such as transplantation from haploidentical donors or cord blood stem cells. Additionally, this collection will address relapse prevention strategies leveraging immunotherapy and novel drugs. Finally, this collection will investigate the mechanisms of escape that leukemic cells can implement to avoid the control of the donor's immune system.
The collection will accept manuscripts in the following research areas:
- Haploidentical SCT in patients with AML
- Transplantation from alternative sources in patients with AML
- Molecular risk and relapse in AML
- Prevention of relapse with new drugs in patients with AML
- Leukemic mechanisms of escape during SCT
- Immunotherapy approaches after SCT in patients with AML
Important Note: Manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in any of the sections of Frontiers in Oncology.
